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Abstract
Intraneoplastic diversity in human tumors is a widespread phenomenon of critical importance for tumor progression and
the response to therapeutic intervention. Insights into the evolutionary events that control tumor heterogeneity would be a
major breakthrough in our comprehension of cancer development and could lead to more effective prevention methods
and therapies. In this paper, we design an evolutionary mathematical framework to study the dynamics of heterogeneity
over time. We consider specific situations arising during tumorigenesis, such as the emergence of positively selected
mutations (‘‘drivers’’) and the accumulation of neutral variation (‘‘passengers’’). We perform exact computer simulations of
the emergence of diverse tumor cell clones over time, and derive analytical estimates for the extent of heterogeneity within
a population of cancer cells. Our methods contribute to a quantitative understanding of tumor heterogeneity and the
impact of heritable alterations on this tumor trait.
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Introduction
Human tumors originate from normal cells that accumulate
genetic and epigenetic changes. The types and numbers of
changes necessary for malignant transformation differ between
tumor types, but a common feature among most types is variability
in both genotype and phenotype among the cancer cells within a
single tumor [1–3]. These cells can be distinguished by
characteristics such as size, cellular morphology, and antigen
expression as well as in behaviors like cell turnover, motility, cell-
cell interactions, response to treatment, and angiogenic, immuno-
genic, and metastatic ability [4,5]. This tumor diversity has
profound clinical implications for disease progression, diagnosis,
therapeutic responses, and the choice of optimal treatments. Since
biopsies used for diagnostic purposes sample only a small region of
a tumor, they might not be representative of the totality of a
diverse cancer cell population; hence treatment choices based
upon such diagnostic samples might not inhibit all tumor cells and
thereby lead to residual disease in many patients. Similarly, the use
of biomarkers may lead to inappropriate conclusions about the
type, stage, and prognosis of a tumor. The therapeutic response of
tumors also depends on the composition of the cell population:
experimental tumors composed of multiple clones display different
sensitivity to cytotoxic drugs as compared to monoclonal tumors,
since clonal interactions can either potentiate or inhibit therapeu-
tic efficacy [6]. Therefore, intratumor heterogeneity adds an
additional level of complexity to the study of cancer development
and poses challenges for the development of successful therapies.
Determining the evolutionary events that control tumor
heterogeneity would increase our understanding of cancer
development and could lead to more effective prevention methods
and therapies. In this paper, we design a mathematical model of
tumor heterogeneity and investigate the evolutionary dynamics of
this tumor trait. The present work contributes to the study of
tumor diversity using computational modeling [7–14]. Diversity
and the accumulation of mutations have also been the subject of
many research efforts in evolutionary theory [15–27]. The models
presented in the population genetics literature generally consider
cells undergoing sexual reproduction and situations with weak
selection. However, the dynamics of selective sweeps of advanta-
geous mutations differ between asexually and sexually reproducing
populations, and the types of modeling approaches used to
examine scenarios with weak selection cannot be applied to
situations with strong selection such as those arising during cancer
evolution. Hence a novel mathematical framework is necessary to
investigate the extent of heterogeneity of an asexually evolving
population accumulating alterations with large fitness effects over
time. The model presented in this paper serves as a toy model to
investigate the dynamics of tumor heterogeneity and the impact of
heritable alterations on diversity. We consider an idealized
mathematical model in which cells proliferate according to a
stochastic process in which they maintain a strictly constant
population size. The assumption of a constant population size may
describe pre-malignant tissues in which genetic and epigenetic
alterations lead to diversity before more aggressive clones arise.
Additionally, such a model applies to cancer cell populations
which have reached a carrying capacity due to resource limitation,
the lack of an appropriate phenotype conferred by specific
mutations, or other restrictions to continued growth such as the
absence of angiogenesis, presence of a strong immune response, or
tissue and compartment boundaries. Although the tumor cells may
be able to continue to expand exponentially once those barriers
are removed, for the duration of time until the evolution of a more
aggressive phenotype, the assumption of a constant population size
may apply. Therefore, we here analyze a model restricting the
number of cells to a constant value over time.
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Consider a population of N cancer cells following a stochastic
process [28]: at each time step, a cell is chosen for replication
proportional to fitness (i.e. growth rate), and its offspring replaces
another randomly chosen cell. The population size remains strictly
constant during the period of observation; the population size can,
however, increase in response to the accumulation of specific
(epi)genetic changes. During each cell division, a new genetic or
epigenetic alteration may emerge in one of the two daughter cells.
We consider two types of alterations: those that do not alter the
growth or death rate of the cell (neutral or ‘‘passenger’’ changes),
and those that confer a fitness advantage to the cell. The latter
mutations may be ‘‘driver’’ alterations that contribute to tumor
progression and malignancy. Deleterious mutations, i.e. those that
decrease cellular fitness, are not considered since they will likely be
lost from the population. Neutral and advantageous changes arise
at rates u and v per cell division, respectively. Each time a
mutational event occurs, a novel cell type arises (Fig. 1). This
assumption is known as the infinite alleles model in population
genetics [29]. Denote those cell types that do not harbor an
advantageous mutation as type A cells (including all cell types
carrying different numbers of neutral mutations), and those cells
that harbor a specific advantageous mutation as type B cells. The
growth rates of type A and B cells are given by R and R+S,
respectively, while both their death rates are given by D. Note that
we assume the fitness effect of the advantageous alteration to act
on the growth rather than the death rate; alternative assumptions
are possible. Denote by H(t) the probability at time t that a
randomly chosen pair of cells is genetically distinct; this quantity is
called tumor heterogeneity.
In tumors that follow the stem cell hypothesis – i.e. the idea that
only a small subset of tumor cells possesses unlimited self-renewing
abilities [30], only cancer stem cells can accumulate variability that
will persist in the population. All alterations arising in transit-
amplifying or terminally differentiated cells will eventually be lost
from the system, unless these changes themselves confer self-
renewing capabilities to cells. Here transit-amplifying cells are
defined as those cells that possess the ability to undergo a limited
number of cell replication events before undergoing apoptosis or
differentiating further; unlike self-renewing cells, these cells cannot
persist indefinitely in a tissue. Therefore, in tumors that are
replenished by a small population of cancer stem cells, we consider
that heterogeneity of transit-amplifying cells is proportional to the
heterogeneity of cancer stem cells. Mutations conferring self-
renewal propensities to transit-amplifying cells are not considered
to contribute to the total (long-term) heterogeneity in this case. In
tumor types that do not follow the cancer stem cell model, all cell
types may accumulate alterations that have the potential to persist
in the population, and therefore all tumor cells are included in the
model describing tumors of this latter type. Mathematical models
describing more complex population structures will be the topic of
future investigations.
Computer simulations
We perform exact computer simulations of the stochastic
process; see the supplement online for the source code of the
simulations. There are two categories of cell types: the cell types
that harbor only neutral alterations (type A cells), and the cell types
that additionally carry an advantageous mutation (type B cells).
Denote their respective abundances by xi and yi, where i~0,:::,I
enumerate the individual cell types. The quantity x0 denotes the
number of type A cells that carry no mutations, while y0 denotes
the number of type B cells that harbor no neutral mutations. The
index i~0,:::,I enumerates the individual cell types, where I
denotes the maximum number of types for type A and B cells. This
maximum number may be dictated by the number of ways in
which genetically distinct cells can arise, or alternatively by the
number of ways in which currently available genome profiling
methods can distinguish differences between cells; in the latter
case, differences are only noted when they occur in those parts of
the genome which are profiled in a given study, and may
underestimate the true extent of diversity in a tumor sample.
Initially, there are N unmutated cells, x0(0)~N, while y0(0)~0
and xi(0)~yi(0)~0 for i~1,:::,I. At each time step of this
stochastic process, one cell is chosen for reproduction at random,
but proportional to fitness. If there are j type B cells with fitness
R+S in a population of N-j type A cells with fitness R, then the
probability that a type B cell is chosen for reproduction is
(RzS)j=½(RzS)jzR(N{j) . The chosen cell produces a
daughter cell, possibly with a mutation, which replaces another
randomly chosen cell. The total number of cells remains strictly
constant. This stochastic process is known as the Moran model
[28]. Each time a mutational event occurs, a new cell type is
created; for instance, a cell of type 3 may produce a cell of type 9,
if there are already 8 cell types present. For each parameter set, we
perform many independent runs of the stochastic process to
account for random fluctuations, and determine the heterogeneity
of cells as
Figure 1. A mathematical model of tumor heterogeneity. We consider a population of N tumor stem cells which accumulate mutations. Each
time a mutational event occurs, a new cell type is created. Cell types are enumerated i=0,1,…,I. The extent of heterogeneity at time t is measured
by Simpson’s index shown below, which incorporates the number of cells of each type at time t, xi(t), and the total number of cells, N.
doi:10.1371/journal.pone.0017866.g001
Intratumor Heterogeneity
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for each time t (Fig. 1). This quantity is known as Simpson’s index
[31].
The dynamics of heterogeneity due to neutral variation
Let us first investigate the level of heterogeneity of a population
of type A tumor cells with growth rate R and death rate D,i n
which neutral alterations arise with probability u per cell division.
We will consider advantageous mutants in a later section. During a
small time interval of length Dt, a cell division, death, or mutation
event may occur. Starting from N cells at time t, there are
W~N½1z(R{D)Dt  cells at time tzDt: the number of cells that
remain unchanged during Dt is given by N½1{(RzD)Dt , the
number of cells that die during Dt is given by NDDt, the number
of cells that divide without mutating is given by NR(1{u)Dt
(producing 2NR(1{u)Dt cells at time tzDt), and the number of
cells that divide while mutating is given by NRuDt (producing
2NRuDt cells at time tzDt, half of which carry the new
mutation). Then the total number of cells at time tzDt except
novel mutants is given by Y~N½1z(R{D)Dt{RuDt . The
probability that a randomly chosen pair of cells has exactly the
same genotype is given by
1{H(tzDt)~
½1=2Y(Y{1){NR(1{u)Dt (1{H(t))zNR(1{u)Dt
1=2W(W{1)
:
ð2Þ
The factor 1/2 arises since each pair of cells is counted only once.
When neglecting terms of higher order of Dt, we obtain
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With H(0)~0, we obtain
H(t)~
Nu
Nuz1
1{exp½{2R(uz1=N)t  ðÞ : ð5Þ
This quantity increases smoothly from 0 to the asymptotic level,
H(?)~Nu=(Nuz1). Figure 2 shows the dynamics of heteroge-
neity as given by equation (5) and the exact computer simulation of
the stochastic process.
The dynamics of heterogeneity due to neutral and
advantageous variation
Let us next discuss the situation in which a single type B cell
carrying an advantageous mutation arises at time t1. This cell has
division and death rates of R+S and D, respectively, and its lineage
accumulates neutral variation at rate u per cell division. Denote
the number of type B cells at time t by n(t) while the total
population size is N. Type B cells have a per capita division rate of
b, which includes the fitness values of both type A and B cells since
it is the outcome of their competition. The probability of cell
division of type B cells in a time interval of length Dt is given by
bnDt~DNDt
(RzS)n
(RzS)nzR(N{n)
: ð6Þ
Then the per capita net growth rate of type B cells is given by
b{D~½S(1{n=N)D =½RzSn=N  and the population of those
cells grows according to
dn
dt
~(b{D)n ð7Þ
with initial condition n(t1)~1.
To derive the expression for heterogeneity among type B cells
over time, recall equation (5). With initial condition HBB(t1)~0
and given equation (7), the heterogeneity among type B cells is
then given by
dHBB
dt
~{2
(RzS)D
RzSn=N
uz
1
n
  
HBBz2
(RzS)D
RzSn=N
u: ð8Þ
Similarly, the per capita cell division rate of type A cells is given
by a~RD=½RzSn=N . Then the heterogeneity among type A
cells over time, HAA(t), is given by
dHAA
dt
~{2
RD
RzSn=N
uz
1
N{n
  
HAAz2
RD
RzSn=N
u, ð9Þ
where HAA(t1)~H(t1) from equation (5). Finally, the total
heterogeneity is composed of heterogeneity among type A cells,
HAA(t), heterogeneity among type B cells, HBB(t), and heteroge-
neity between type A and B cells, HAB(t). If the type B lineage
does not have the possibility of going extinct, then the total
heterogeneity of the population is given by
H1(t)~
N{n
N
   2
HAA(t)z2
n
N
  N{n
N
  
HAB(t)z
n
N
   2
HBB(t):
ð10Þ
Considering the possibility of extinction of type B cells, the total
heterogeneity becomes
H2(t)~ 1{
R
RzS
  
H1(t)z
R
RzS
H(t): ð11Þ
.
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bility that a newly arisen type B cell survives the stochasticity when
its clone is small; this calculation is based on the branching process
approximation (e.g., [32]). Since cell types A and B differ by at least
theadvantageousmutation,wecanconsiderHAB(t)~1 foralltimes
t. Figure3 shows the dynamicsofheterogeneityasgivenby equation
(11) and the results of the exact stochastic computer simulation.
Alternatively, consider the case in which the advantageous
mutation cannot be detected by currently used screening methods.
In that case, the only loci contributing to heterogeneity are those
that do not cause a fitness difference when mutated – i.e., neutral
variation. Then the heterogeneity between type A and B cells at
time t, HAB(t), is determined by considering the ancestral cell
lineages giving rise to any pair of cells. Recall that the number of
type B cells existing at time tzDt is n½1z(b{D)Dt , and the
number of cells harboring a novel neutral mutation at time tzDt is
nbuDt. Then the probability that a cell accumulates a mutation between
times tand tzDt is given by nbuDt=½n(1z(b{D)Dt) &buDt.A sw e
trace the ancestral lineage of a type B cell from time t back to
time t1, the probability that no mutation occurs during this time
interval is given by exp½{
ðt
t1
b(t)udt . Similarly, the probability
that no mutation occurs in the ancestral lineage of a type A cell is
given by exp½{
ðt
t1
a(t)udt ,w h e r ea denotes the per capita
division rate of type A cells. Then we have
HAB(t)~ 1{exp {
ð t
t1
(a(t)zb(t))udt
2
6 4
3
7 5
0
B @
1
C Az
H(t1)exp {
ð t
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(a(t)zb(t))udt
2
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3
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ð12Þ
since a pair of type A and B cells are different either because their
ancestral cells at time t1 were different, or because the ancestral
lineage of either cell accumulated a mutation. Equation (12) can
be approximated by
HAB(t)~(1{exp½{2Du(t1{t) )zH(t1)exp½{2Du(t1{t) ð 13Þ
since bwDwa. Figure 4 shows the dynamics of heterogeneity in
the case in which the advantageous mutation cannot be detected,
as given by equation (12), and the results of the exact stochastic
computer simulation for that scenario.
Finally, let us discuss the situation in which type B cells carrying
advantageous mutations arise at rate v per cell division. A cell with
k advantageous mutations has growth and death rates of
R(1zS=R)
k and D, respectively, and its lineage accumulates
neutral variation at rate u per cell division. In this case, the rate at
which a selective sweep occurs is given by NvS=(RzS). Then the
expected mean heterozygosity is given by
Figure 2. Tumor heterogeneity due to neutral variation. A cell
population of fixed size, N, accumulates neutral mutations at rate u per
cell division. All cell types have growth rate R and death rate D. The
figure shows the fit of the exact stochastic computer simulation of this
process with equation (5). In the simulation, heterogeneity is defined as
Simpson’s index, equation (1). Parameters are N~1000, R~D~1,
I~104, and u~10{2 in (a), u~5:10{3 in (b), and u~10{3 in (c), and
results are averaged over 100 simulation runs.
doi:10.1371/journal.pone.0017866.g002
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In this equation, the first term corresponds to the case in which
one or more selective sweeps of advantageous mutants occur
before time t, while the second term corresponds to the case in
which no selective sweep has occurred until time t. By substituting
equation (1) for H(t), we obtain
EH (t) ½  ~
Nu
Nuz1
1{e½{at {
a
azb
1{e½{(azb)t  ðÞ ze½{at  1{e½{bt  ðÞ
  
,
ð15Þ
where a~NvS=(RzS) and b~2(uz1=N). In the limit of
infinitely large time t, this expression becomes E½H(?) ~
Nub=½(Nuz1)(azb) . Figure 5 shows the dynamics of heteroge-
neity in the case in which advantageous mutations arise at rate v
while neutral mutations are accumulated at rate u per cell division;
we show equation (15) and the results of the exact stochastic
computer simulation for that scenario.
So far, we have discussed the dynamics of intratumor
heterogeneity in populations of constant size. However, since
tumors expand over time, it is also important to consider the
accumulation of variation in growing tumor cell populations. In
cases in which the expansion of a tumor cell population is driven
by the accumulation of (epi)genetic alterations, the model
described above can be used to describe the kinetics of diversity
during those times when the population size is roughly constant –
i.e., between the events of accumulation of a novel advantageous
mutation. Once such a mutation has arisen, the population grows
until reaching a new steady state level. Our model is useful for
describing the accumulation of variation during these fixed-size
periods. Alternatively, an exponentially growing population can be
considered in which alterations arise; a useful stochastic process for
this scenario is the branching process model in which cells divide
in a binary fashion, and the population grows (or declines) on
average exponentially. Such a model is the topic of other work
[33,34].
Discussion
Intratumor heterogeneity is a key mechanism underlying tumor
progression and the frequent lack of therapeutic responses.
Although tumors are thought to originate from a single cell that
Figure 3. Tumor heterogeneity due to neutral and positively
selected variation. A cell population of fixed size, N, accumulates
neutral mutations at rate u per cell division. All neutral mutants have
growth rate R and death rate D. Additionally, a positively selected
mutant arises at time t1 in the population. Its lineage has growth rate
RzS and death rate D. The figure shows the fit of the exact stochastic
computer simulation of this process with equation (11). In the
simulation, heterogeneity is defined as Simpson’s index, equation (1).
Parameters are N~1000, R~D~1, I~104, u~10{2, and S~1 in (a),
S~3 in (b), and S~100 in (c), and results are averaged over 100
simulation runs.
doi:10.1371/journal.pone.0017866.g003
ð15Þ
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by the time of diagnosis, most cancers exhibit widespread
heterogeneity. This tumor diversity does not only complicate the
profiling of cancers, since a sample may not be representative of
the whole, but also decreases the likelihood of cure due to
therapeutic interventions since resistant clones may already pre-
exist therapy. An understanding of the evolutionary forces driving
intratumor heterogeneity would enhance our understanding of
tumorigenesis and may allow us to more effectively plan
treatments.
In this paper, we have designed a stochastic mathematical
model of the accumulation of (epi)genetic alterations in popula-
tions of cells to estimate the extent of heterogeneity over time
(Fig. 1). We have studied this model with exact stochastic
computer simulations (Figs. 2–5) and have also derived analytical
approximations for the dynamics of heterogeneity in the
population. We have considered two different types of heritable
alterations that may arise during cell divisions: neutral variation
that does not change the fitness of cells, but leads to the emergence
of a new cell type that can be distinguished from the resident
cancer cell population with molecular profiling techniques, and
advantageous alterations which lead to a fitness increase of the cell
and potentially a selective sweep in the population. Here selective
sweep refers to the reduction or elimination of variation in a cell
population due to recent and strong positive selection [35]. We
have neglected disadvantageous alterations since in large tumors,
cells carrying such alterations are likely unable to establish a
surviving clone, but go extinct due to their deleterious character-
istics. The population of cells at risk of accumulating these
alterations consists of those cells that are maintained in the
population for long time horizons; in tumor types adhering to the
cancer stem cell hypothesis, only cancer stem cells have self-
renewal propensities and hence, genetic variability accumulated
within them may persist in the population rather than being lost
due to differentiation and death of its carrier cell. Heterogeneity
accumulated in progenitors and differentiated cells can contribute
to a snapshot analysis of diversity, but cannot be maintained for
long time horizons. In the case of tumors not following the cancer
stem cell model, all tumor cells potentially possess self-renewal
abilities and are therefore part of the population of cells which
accumulate (epi)genetic variability.
Our evolutionary model demonstrates that the accumulation of
neutral variation in a population leads to an increase in
heterogeneity until a maximum extent is reached (Fig. 2). This
maximum value is dictated by the number of cells in the
population as well as the mutation rate giving rise to new cell
types. After introduction of an advantageous mutation, the extent
of heterogeneity decreases rapidly as the advantageous clone
spreads through the population, but afterwards rebounds as
neutral variation continues to be accumulated in this clone (Figs. 3
Figure 4. Tumor heterogeneity when only neutral variation can
be detected. A cell population of fixed size, N, accumulates neutral
mutations at rate u per cell division. All neutral mutants have growth
rate R and death rate D. Additionally, a positively selected mutant arises
at time t1 in the population. Its lineage has growth rate RzS and death
rate D. This mutation, however, cannot be detected when measuring
heterogeneity in the population. The figure shows the fit of the exact
stochastic computer simulation of this process with equation (12). In
the simulation, heterogeneity is defined as Simpson’s index, equation
(1), and wild type cells as well as cells harboring the advantageous
mutation are considered as one cell type. Parameters are N~1000,
R~D~1, I~104, u~10{2, and S~1 in (a), S~3 in (b), and S~100 in
(c), and results are averaged over 1000 simulation runs.
doi:10.1371/journal.pone.0017866.g004
Intratumor Heterogeneity
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population over time, then the extent of heterogeneity is
maintained at a lower level since the advantageous clones arise
stochastically and decrease the average heterogeneity across the
cancer cell population (Fig. 5). Our model provides an
understanding of the consequences of accumulating neutral and
advantageous variation in a tumor; such knowledge aids in the
interpretation of cancer genomic data as well as relays an
understanding of the basic biology and kinetics of tumors.
We have chosen to concentrate on the behavior of tumor cells
which accumulate (epi)genetic changes while proliferating in a
fixed-size population or niche. Situations with exponentially
increasing population sizes are the topic of follow-up work
[33,34]. For clarity, we have neglected other important aspects
contributing to tumorigenesis, such as interactions of tumor cells
with the immune system and microenvironment, cell-cell interac-
tions, competition for resources and space, as well as the effects of
exogenous mutagenic factors and inherited predispositions. These
factors will be considered in future contributions.
To validate the predictions of this model and further the
understanding of tumor diversity, detailed experimental analyses
of tumor heterogeneity are necessary. For instance, the number
and frequencies of (epi)genetically or morphologically diverse
clones in a tumor should be ascertained along with the variability
of these quantities when comparing tumors from different
patients or different sites within the same patient, such as
primary and metastatic lesions. With such data, it will be possible
to relate the extent of diversity to clinically important covariates
like survival, proliferation indices, invasiveness, sensitivity to
therapy, etc. Such studies have recently been initiated [36–38]
and will enhance our understanding of the role of tumor diversity
in cancer progression and the response to treatment. Further-
more, evolutionary parameters such as growth and death rates,
mutation rates, and the ability of different cell types to migrate,
adhere and invade are needed to accurately describe the
dynamics of diversity. The values of such parameters remain
unknown for many cell and mutation types, but are necessary for
progress in this field. Finally, the role of the immune system and
microenvironment in tumor progression and diversity must be
delineated to design accurate mathematical models. Although
such studies have been initiated [39,40], many open questions
remain. In summary, experimental methodologies to profile
single cells – both tumor and microenvironmental – from
neoplasms at multiple stages of their evolution are necessary
such that, with the help of appropriate analysis tools, the clinical
management of patients with premalignant lesions or cancer can
be improved.
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Figure 5. Tumor heterogeneity due to continuously arising
neutral and advantageous variation. A cell population of fixed
size, N, accumulates neutral mutations at rate u per cell division and
advantageous mutations at rate v per cell division. All neutral mutants
have growth rate R and death rate D, while a cell with k advantageous
mutations has growth and death rates of R(1zS=R)
k and D. The figure
shows the fit of the exact stochastic computer simulation of this
process with equation (15). In the simulation, heterogeneity is defined
as Simpson’s index, equation (1). Parameters are N~1000, R~D~1,
I~104, u~10{2, S~1000, and v~10{5 in (a), v~5:10{6 in (b), and
v~10{6 in (c), and results are averaged over 1000 simulation runs.
doi:10.1371/journal.pone.0017866.g005
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